Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cited by
Items 401–500 of 567
Senescence and Senescence-Related Disorders
Wang, Z. P., & Inuzuka, H. (2013) · InTech eBooks · doi:10.5772/56158 · Cited by 12
Chu, A. M., André, J., Rich, P. A., Leachman, S. A., & Thompson, C. T. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13457 · Cited by 10
“The CDKN2A gene, which regulates the cell cycle at the G1/S checkpoint, has been shown to be important in a variety of cancers, including melanoma, and loss of p16 in primary invasive melanoma correlates with overall disease prognosis and metastasis-free survival.(5) It is important to note that loss of p16 IHC staini…”
BackgroundNonparametric estimation of LOH using Affymetrix SNP genotyping arrays for unpaired samples
Huggins, R., Li, L., Lin, Y.-C., Yu, A. L.-T., & Yang, H. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0340-9 · Cited by 10
Role of the E2F1-p19ARF-p53 Pathway in Ischemic Acute Renal Failure
Tanaka, H., Terada, Y., Okado, T., Inoshita, S., Kuwahara, M., & Sasaki, S. (2005) · Nephron Physiology · doi:10.1159/000086642 · Cited by 11
Azzopardi, S., Pang, S., Klimstra, D., & Du, Y. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.003 · Cited by 11
“The p53 and p16/p19 genomic loci were flanked with loxP sites [36,37] to allow generate nullizygous gene loci by Cre-mediated recombination.”
MethodMolecular cloning and characterization of the human p19INK4d gene promoter
Matsuzaki, Y., Miyazawa, K., Yokota, T., Hitomi, T., Yamagishi, H., & Sakai, T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02647-9 · Cited by 11
Roca, R., Kypta, R. M., & Vivanco, M. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0634912100 · Cited by 12
Senescence and Cell Cycle Control
Kiyokawa, H. (2006) · Springer eBooks · doi:10.1007/400_001 · Cited by 12
The INK4a/ARF Locus and Human Cancer
Enders, G. H. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:197 · Cited by 14
Sharpless, N. E. (2003) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2003.33.pe24 · Cited by 14
Chan, W. L., Bucher, C. H., Goldes, J., Ma, A. C., Steiner, M., Willie, B. M., Mundlos, S., & Kornak, U. (2024) · Aging Cell · doi:10.1111/acel.14322 · Cited by 10
Oval cell proliferation in p16INK4a expressing mouse liver is triggered by chronic growth stimuli
Ueberham, E., Lindner, R., Kamprad, M., Hiemann, R., Hilger, N., Woithe, B., Mahn, D., Cross, M. A., Sack, U., Gebhardt, R., et al. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00178.x · Cited by 11
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Farahmand, P., Gyurászová, K., Rooney, C., Iraolagoitia, X. L. R., Jayasekera, G., Hedley, A., Johnson, E. R., Chernova, T. A., Malviya, G., HALL, H. G., et al. (2023) · Frontiers in Toxicology · doi:10.3389/ftox.2023.1200650 · Cited by 9
“, 2000) and Cdkn2a knockout (Krimpenfort et al., 2001) mice were described previously.”
An INKlination for epigenetic control of senescence
Peters, G. G. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1108-1133 · Cited by 12
Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells
Filograna, A., Tito, S. D., Monte, M. L., Oliva, R., Bruzzese, F., Roca, M. S., Zannetti, A., Greco, A., Spano, D., Ayala, I., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03044-5 · Cited by 8
A cancer-prone case with a background of methylation of p16 tumor suppressor gene.
Hibi, K., Koike, M., Nakayama, H., Fujitake, S., Kasai, Y., Ito, K., Akiyama, S., & Nakao, A. (2003) · PubMed · Cited by 8
Adamović, T., Hamta, A., Roshani, L., Lü, X., Röhme, D., Helou, K., Klinga‐Levan, K., & Levan, G. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.02.016 · Cited by 8
The INK4A/Arf Network — Cell Cycle Checkpoint or Emergency Brake?
del Arroyo, A. G., & Peters, G. G. (2005) · Advances in experimental medicine and biology · doi:10.1007/1-4020-3764-3_8 · Cited by 10
p16 Ink4a Interferes with Abelson Virus Transformation by Enhancing Apoptosis
Sachs, Z., Sharpless, N. E., DePinho, R. A., & Rosenberg, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3304-3311.2004 · Cited by 8
“suppressing tumor development in humans and mice (22, 35, 40, 43, 44).”
BackgroundInfluentialResistance Mechanisms to Cyclin-Dependent Kinase Inhibitors
Wiedemeyer, W. R. (2018) · Resistance to Targeted Anti-Cancer Therapeutics · doi:10.1007/978-3-319-67932-7_8 · Cited by 7
Flaherty, K. T. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00816.x · Cited by 7
“Within the next year, clinical trials will begin testing the therapeutic potential of drugs targeting the PI3 kinase and cyclin-dependent kinase pathways, which have been demonstrated in years past as critical in contributing to invasiveness and cell cycle dysregulation as well as genetic predisposition (Krimpenfort e…”
BackgroundAktary, Z., McMahon, M., & Larue, L. (2017) · Springer eBooks · doi:10.1007/978-1-4614-7322-0_32-1 · Cited by 9
Is cellular senescence important in pediatric kidney disease?
Jacobi, C., Hömme, M., & Melk, A. (2011) · Pediatric Nephrology · doi:10.1007/s00467-010-1740-6 · Cited by 8
Kim, K. H., Cho, Y., Lee, J., Jeong, H., Lee, Y., Kim, S. I., Kim, C., Lee, H., & Nam, K. T. (2019) · Scientific Reports · doi:10.1038/s41598-019-47676-6 · Cited by 10
Cosgrove, D., Park, B. H., & Vogelstein, B. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm005 · Cited by 8
Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci
Wong, K. M., King, D. A., Schwartz, E. K., Herrera, R. E., & Morrison, A. J. (2022) · Life Science Alliance · doi:10.26508/lsa.202101134 · Cited by 8
“In the case of telomeres speci fi cally, previous studies demonstrate their sensitivity to UV-induced lesion formation (Kruk et al, 1995; Rochette & Brash, 2010), which can persist for days to weeks in cell culture (Mitchell et al, 1999; B´erub´e et al, 2018).”
Regulation of the Cell Cycle and Interventional Developmental Therapeutics
Ivanchuk, S. M., & Rutka, J. T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088410-0/50047-0 · Cited by 6
Francis, S. M., Chakrabarti, S., & Dick, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016434 · Cited by 6
Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis
Nilsson, L. M., Keller, U. B., Yang, C., Nilsson, J. A., Cleveland, J. L., & Roussel, M. F. (2006) · Oncogene · doi:10.1038/sj.onc.1210104 · Cited by 8
“Of the four Ink4 family members (p16, p15, p18 and p19), the first three possess tumor suppressor activities in humans and mice (Franklin et al., 1998; Ruas and Peters, 1998; Latres et al., 2000; Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundResultChen, Y., Gu, L., & Deng, D. (2014) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2014.04.012 · Cited by 6
Wang, Y.-J., Chang, H., Kuo, Y.-C., Wang, C., Siao, S.-H., Chang, L. W., & Lin, P. (2010) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2010.11.082 · Cited by 7
p16Ink4a and p19Arf: terrible twins
Weitzman, J. B. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02190-6 · Cited by 6
von Brandenstein, M., Schlosser, M., Richter, C., Depping, R., & Fries, J. W. U. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.014 · Cited by 6
“Its overexpression or loss of function is commonly related to oncogenesis (Hui et al., 2000; Krimpenfort et al., 2001) such as in renal cell carcinoma (Maruschke et al.”
BackgroundModeling Cell Cycle Control and Cancer with pRB Tumor Suppressor
Yamasaki, L. (2006) · Springer eBooks · doi:10.1007/b136682 · Cited by 7
The Role of Systemic Filtrating Organs in Aging and Their Potential in Rejuvenation Strategies
Kassab, A., Rizk, N. M., & Prakash, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084338 · Cited by 5
“21 [92] Chordin-Like Protein 1 CHRDL1 51.”
Exploring cellular senescence as a tumor suppressor mechanism
Carnero, A., Blanco‐Aparicio, C., Blanco, F., Castro, M. E., Guijarro, M. V., Fominaya, J. M., Link, W., Martínez, J. F., Moneo, V., Renner, O., et al. (2003) · Revista de Oncología · doi:10.1007/bf02711481 · Cited by 9
Cellular Senescence as a Target in Cancer Control
Carnero, A. (2007) · Current Cancer Therapy Reviews · doi:10.2174/157339407780126629 · Cited by 6
Gray‐Schopfer, V. C., & Bennett, D. C. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch24 · Cited by 6
Halaban, R., & Moellmann, G. E. (2006) · Wiley eBooks · doi:10.1002/9780470987100.ch22 · Cited by 5
Familial Melanoma Genes, Melanocyte Immortalization, and Melanoma Initiation
Bennett, D. C. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_10 · Cited by 5
Garcia-Diaz, C., Mereu, E., Clements, M., Pöysti, A., Gálvez-Cancino, F., Castillo, S. P., Courtot, L., Ruiz, S., Roncaroli, F., Yuan, Y., et al. (2021) · bioRxiv · doi:10.1101/2021.06.11.447915 · Cited by 3
Using a systems biology approach to understand and study the mechanisms of metastasis
Ha, N., & Hunter, K. W. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1237 · Cited by 7
Survival of Lung Cancer Patients Dependent on the LOH Status for DMP1, ARF, and p53
Fry, E. A., Niehans, G. E., Kratzke, R. A., Kai, F., & Inoue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217971 · Cited by 4
Mammalian Development and Cancer: A Brief History of Mice Lacking D-Type Cyclins or CDK4/CDK6
Kalaszczyńska, I., & Ciemerych, M. A. (2017) · Current cancer research · doi:10.1007/978-3-319-64451-6_2 · Cited by 4
Molecular cloning and characterization of the INK4a and ARF genes in naked mole-rat
Miyawaki, S., Kawamura, Y., Hachiya, T., Shimizu, A., & Miura, K. (2015) · Inflammation and Regeneration · doi:10.2492/inflammregen.35.042 · Cited by 4
Early diagnosis of melanoma: what do we know?
Yee, E., Hoffman, R. M., & Berwick, M. (2007) · Cited by 4
Quelle, D. E., Nteeba, J., & Darbro, B. W. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.30060-8 · Cited by 6
The Role of Endothelin 3 in Melanoma Progression and Metastasis
Chin, N. L. (2015) · FIU - Digital Commons (Florida International University) · doi:10.25148/etd.fidc000185 · Cited by 3
The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo
Silconi, Ž. B., Rosic, V., Benazic, S., Radosavljevic, G. D., Mijajlović, M. Ž., Pantic, J. M., Ratković, Z., Radić, G. P., Arsenijević, A., Milovanović, M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158161 · Cited by 3
Kotake, Y., & Kitagawa, M. (2015) · Springer eBooks · doi:10.1007/978-4-431-55576-6_10 · Cited by 4
Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics
Malumbres, M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_10 · Cited by 5
Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development
Wangari‐Talbot, J., Goydos, J. S., & Chen, S. (2010) · Pharmaceuticals · doi:10.3390/ph3092821 · Cited by 4
“A major drawback of these models is that the development of melanoma has a long latency period and frequently requires more than one carcinogen to induce tumors which tend to metastasize at very low rates or are not metastatic at all [9,60,61].”
Molecular genetics of acute lymphoblastic leukemia
Mullighan, C. G. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.008 · Cited by 4
Glioma Oncogenesis and Animal Models of Glioma Formation
Lyustikman, Y., & Lassman, A. B. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.09.005 · Cited by 3
Schubert, N. A., van Hooff, S. R., Schild, L. G., Ober, K., Hortensius, M., van den Handel, K., Essing, A. H. W., Koopmans, B., Boeije, M., Proost, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.27.465137 · Cited by 4
Li, B., Chen, L., Su, Y., Meng, J., & Su, Z. (2026) · Biogerontology · doi:10.1007/s10522-026-10390-8 · Cited by 2
“For example, mouse embryonic fibroblasts lacking p53 (Kamijo et al. 1997) but not Ink4a (p16) or RB (Sharpless et al. 2001; Krimpenfort et al. 2001; Sage et al. 2000) escape Ras-induced senescence.”
The ARF protein in tumor suppression: lessons from mouse models and human tumors
Rodríguez, I. P. (2004) · Clinical & Translational Oncology · doi:10.1007/bf02710031 · Cited by 2
Malignant Epithelioid Neoplasm versus Dedifferentiated Malignant Melanoma: A Case Report
Rosenberg, A., Wei, C., Grabie, Y. Y., Chain, S., Thapa, S., & Vatandoust, G. (2024) · Diseases · doi:10.3390/diseases12090196 · Cited by 2
“Our case showed MAP2K1 gene mutations and p16INK4a loss, which are commonly found in melanoma malignancies [12,13].”
BackgroundCell Death in Response to Genotoxic Stress and DNA Damage
Lopez‐Bergami, P., & Ronai, Z. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511976094.008 · Cited by 3
Regulation of Cellular Senescence by the Retinoblastoma Pathway
Becker, T. M., & Rizos, H. (2003) · Springer eBooks · doi:10.1007/978-94-017-0669-8_9 · Cited by 2
Greenwood, E. (2001) · Nature reviews. Cancer · doi:10.1038/35106018 · Cited by 2
Shah, K., Patel, S., Mirza, S., Raval, A. P., & Rawal, R. (2016) · Meta Gene · doi:10.1016/j.mgene.2016.11.001 · Cited by 2
Tonks, I. D., Mukhopadhyay, P., Schroder, W. A., Sorolla, A., Mould, A. W., Handoko, H. Y., Ferguson, B., Muller, H. K., Keith, P., Hayward, N. K., et al. (2017) · Oncogene · doi:10.1038/onc.2016.511 · Cited by 2
Preclinical Models for Cell Cycle-Targeted Therapies
Malumbres, M. (2006) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-5133-3_13 · Cited by 2
“Inactivating mutations in single INK4 inhibitors in the mouse, including p16INK4a [32,33], p15INK4b [34] and p18INK4c [34,35], also result in tumor susceptibility.”
BackgroundGenetic and Molecular Pathology of Melanoma
Piepkorn, M. W. (2014) · Springer eBooks · doi:10.1007/978-3-642-38385-4_3 · Cited by 2
Moschos, S. J., Konstantinopoulos, P. A., & Kirkwood, J. M. (2005) · Cancer chemotherapy and biological response modifiers · doi:10.1016/s0921-4410(04)22025-7 · Cited by 2
Understanding Melanocyte Transformation – A Work in Progress
Wangari‐Talbot, J., Goydos, J. S., & Che, S. (2011) · InTech eBooks · doi:10.5772/19753 · Cited by 1
Rôle protecteur de la voie fibrates/p16INK4Adans les lesions vasculaires occlusives
Gizard, F., & Staels, B. (2006) · médecine/sciences · doi:10.1051/medsci/2006224351 · Cited by 1
“Jusqu’alors, p16 était connu comme gène suppresseur de tumeur, sa perte de fonction étant impliquée dans l’initiation et le développement de certains cancers : leucémie lymphoblastique aiguë, lymphome, carcinome pulmonaire et mélanome [6, 12, 13].”
BackgroundTsapras, A., Emmanouil, T., Emmanouil, P., Balas, C. J., Makris, A., Tsatsanis, C., & Stathopoulos, E. N. (2016) · IEEE International Conference on Imaging Systems and Techniques (IST) · doi:10.1109/ist.2016.7738255 · Cited by 1
Aktary, Z., McMahon, M., & Larue, L. (2019) · Springer eBooks · doi:10.1007/978-1-4614-7147-9_32 · Cited by 1
Moira, R. J., & Stephen, P. S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_77 · Cited by 1
Effect of cell cycle inhibitor p19ARF on senescence of human diploid cell
Bai, X., Chen, X., Hou, K., Zhang, P., Feng, Z., & Fu, B. (2007) · Science in China Series C Life Sciences · doi:10.1007/s11427-007-0024-2 · Cited by 1
Genetische Grundlagen der Kanzerogenese
Bartram, C. R. (2009) · Springer eBooks · doi:10.1007/978-3-540-79725-8_4 · Cited by 4
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Saffroy, R., Lemoine, A., Debuire, B., & Brousse, P. (2004) · Cited by 1
Cellular Senescence Pathways in Mouse and Human
Wadhwa, R., Hasan, M. K., & Kaul, S. C. (2003) · Springer eBooks · doi:10.1007/978-94-017-0669-8_12 · Cited by 2
Philpott, M. P., Bergamaschi, D., & Storey, A. (2007) · Wiley eBooks · doi:10.1002/9780470025079.chap389 · Cited by 1
Darbro, B. W. (2007) · doi:10.17077/etd.2qnj4kik · Cited by 1
“Studies in transgenic knockout mice have suggested that p16 inactivation can confer increased metastatic potential to tumor cells but the associated loss of ARF in many of these experiments has made interpretation of the individual role of p16 loss complicated (Aguirre et al., 2003; Krimpenfort et al., 2001).”
BackgroundThe role of polyhomeotic in polycomb group-mediatedregulation of the tumour suppressor P16INK4A
de Breed, L. A. (2010) · UCL Discovery (University College London) · Cited by 1
Role of Jun dimerization protein 2 (JDP2) in cellular senescence
Huang, Y., Lee, I.-L., Tsai, Y.-F., Saito, S., Lin, Y., Chiou, S., Tsai, E., & Yokoyama, K. K. (2010) · Inflammation and Regeneration · doi:10.2492/inflammregen.30.507 · Cited by 1
CDKN2a (cyclin dependent kinase 2a / p16)
Saffroy, R., Lemoine, A., & Debuire, B. (2011) · Atlas of Genetics and Cytogenetics in Oncology and Haematology · doi:10.4267/2042/38488 · Cited by 1
Dubus, P. R., Malumbres, M., & Ortega, S. (2006) · Enzyme inhibitors series/CRC enzyme inhibitors series · doi:10.1201/9781420005400.ch3 · Cited by 1
A novel role of DNA fragmentation factor as a tumor suppressor through maintaining genomic stability
Yan, B., Wang, H., Bedford, J. S., Dewhirst, M. W., & Li, C. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.10023 · Cited by 1
Zhang, Y., Belote, R. L., Urquijo, M. A., Hansen, M. M. K., Hejna, M., Moustafa, T. E., Liu, T., Lange, D., Vand‐Rajabpour, F., Chang, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269126 · Cited by 3
Genetische Grundlagen der Kanzerogenese
Bartram, C. R. (2004) · Springer eBooks · doi:10.1007/978-3-662-06670-6_4 · Cited by 1
Martino, J. J., & Chen, S. (2007) · Humana Press eBooks · doi:10.1385/1-59259-893-5:275 · Cited by 1
Nehra, R. (2009) · DigitalGeorgetown (Georgetown University Library)
Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy
Han, D., & Smalley, K. S. M. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4939-2143-0_7
Pre-B cell receptor signaling prevents malignant transformation by BCR-ABL1
Trageser, D. (2008) · Univ. Duesseldorf: Duesseldorfer Dokumenten- und Publikationsserver
Analysis of senescence-like growth arrest induced by RUNX1 and its fusion derived oncoproteins
Wolyniec, K. (2008) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.578 · Cited by 1
REGγ Mediated Regulation of p21Waf/Cip1, p16INK4a and p14ARF/p19ARF in Vivo
Li, L., Zhang, P., Wei, H., Wang, W., Yao, L., Li, Y., Zhou, L., Wang, Z., Liu, J., Zhou, L., et al. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.45104
p15INK4b, a Tumor Suppressor in Acute Myeloid Leukemia
Fares, J., Wolff, L., & Bies, J. (2011) · InTech eBooks · doi:10.5772/27758 · Cited by 2
“Its expression is lost by several mechanisms including point mutations, small deletion and epigenetic modifications which have been reported in thousands of human cancers (Serrano et al., 1996; Krimpenfort et al., 2001).”
BackgroundBiomarkers for Melanoma Diagnosis and the Technologies Used to Identify Them
Mori, T., & Kang, J. (2011) · InTech eBooks · doi:10.5772/22454 · Cited by 1
Role of the Ink4a/Arf tumor suppressors in cerebellar development, stem cells and cancer
Lingbeek, M. (2005) · Utrecht University Repository (Utrecht University)
Transcription regulation of human genes: Novel aspects and mechanisms
Denissov, S. (2010) · Radboud Repository (Radboud University)
Targeting of the Myc pathway as a novel approach for cancer therapy
Mo, H. (2006) · Figshare
Interactions Between Myc- and Cyclin-Dependent Kinase Inhibitors in Cancer
Maclean, K. H., & Cleveland, J. L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_12
The Biology and Genetics of Melanoma
Sharpless, N. E., & Chin, L. (2007) · Humana Press eBooks · doi:10.1007/978-1-59259-994-3_15
Role of checkpoint kinase 1 in malignant melanoma
Smith, J. (2013) · Enlighten: Theses (The University of Glasgow)
The Epidemiology, Biology and Genetics of Human Astrocytic Tumours
Bäcklund, L. M. (2005) · Figshare
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.